Herbal complement inhibitors in the treatment of neuroinflammation: Future strategy for neuroprotection

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 413-429

  Kulkarni, Amod P ^a   Kella Way, Laurie A ^a   Kotwal, Girish J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Alternate pathway; Alzheimer's disease (AD); Classical pathway; Complement inhibitors; Cyclooxygenases; Herbal ingredients; HIV associated dementia (HAD); Neurodegeneration; Neuroprotection; Vaccinia virus complement control protein (VCP)

Indexed keywords

ACETYLGAERTNEROSIDE; ANTIINFLAMMATORY AGENT; APIGENIN; APIGENIN DERIVATIVE; AYURVEDIC DRUG; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; ECULIZUMAB; ESTROGEN; FLAVONOID; GAERTNEROSIDE; GESTAGEN; GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; INDOMETACIN; IRIDOID; JUGLANS MANDSHURICA EXTRACT; LUPEOL; LUPEOL LINOLEATE; LUTEOLIN; NIMESULIDE; PEXELIZUMAB; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN SCRRY; RECOMBINANT PROTEIN; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN;

ALOE VERA; ALZHEIMER DISEASE; ANGELICA ACUTILOBA; ASCOPHYLLUM; ASCOPHYLLUM NODOSUM; BOVINE SPONGIFORM ENCEPHALOPATHY; CARDIOTOXICITY; CEDRELA LILLOI; CENTAURIUM SPICATUM; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CRATAEGUS SINAICA; CRATAEVA NURVALA; DIAGNOSTIC VALUE; EDEMA; GLYCYRRHIZA GLABRA; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLAMMATION; JATROPHA; JATROPHA CURCAS; JATROPHA MULTIFIDA LATEX; JUGLANS MANDSHURICA; LIGUSTRUM VULGARE; LITHOSPERMUM EUCHROMUM; MEDICINAL PLANT; MORINDA; MORINDA MORINDOIDES; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROPROTECTION; NONHUMAN; OLIVE TREE; OSBECKIA ASPERA; PARKINSON DISEASE; PERSICARIA LAPATHIFOLIA; PETASITES HYBRIDUS; PHILLYREA LATIFOLIA; PIPER KADSURA; PLANT; ROSEMARY; SOYBEAN; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; TRICHILIA ELEGANS; WEDELIA CHINENSIS;

ALOE VERA; ANGELICA ACUTILOBA; ASCOPHYLLUM; ASCOPHYLLUM NODOSUM; BOVINAE; CEDRELA LILLOI; CRATAEGUS SINAICA; CRATAEVA NURVALA; GLYCINE MAX; GLYCYRRHIZA GLABRA; HUMAN IMMUNODEFICIENCY VIRUS; JATROPHA; JATROPHA CURCAS; JATROPHA MULTIFIDA; JUGLANS MANDSHURICA; LIGUSTRUM VULGARE; LITHOSPERMUM; MORINDA; MORINDA MORINDOIDES; OSBECKIA ASPERA; PETASITES HYBRIDUS; PHILLYREA LATIFOLIA; PIPER KADSURA; POLYGONUM LAPATHIFOLIUM; ROSMARINUS OFFICINALIS; SCHENKIA SPICATA; TRICHILIA ELEGANS; VACCINIA VIRUS; WEDELIA CHINENSIS;

EID: 29744441170     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.020     Document Type: Conference Paper

References (87)

1. BARRINGTON, R. et al. 2001. The role of complement in innate and adaptive immune response. Immunol. Rev. 180: 1-15.
2. GASQUE, P. et al. 2002. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol. Neurobiol. 25: 1-17.
3. TACNET-DELORME, P. et al. 2001. β-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions. J. Immunol. 167: 6374-6381.
4. SANDERS, M.E. et al. 1986. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136: 4456-4459.
5. SELLEBJERG, F. et al. 1998. Intrathecal activation of the complement system and disability in multiple sclerosis. J. Neurol Sci. 157: 168-174.
6. ROMI, F. et al. 2005. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J. Neuroimmunol. 158: 191-194.
7. MCGEER, P.L. & E.G. MCGEER. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10: S3-S7.
8. SEWELL, D.L. et al. 2004. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. 155: 55-63.
9. ANDERSON, A.J. et al. 2004. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21: 1831-1846.
10. BRUDER, C. et al. 2004. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol. Immunol. 40: 949-961.
11. STOIBER, H. et al. 2005. Complement-opsonized HIV: the free rider on its way to infection. Mol. Immunol. 42: 153-160.
12. MABBOTT, N.A. et al. 2001. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat. Med. 7: 485-487.
13. KLEIN, M.A. et al. 2001. Complement facilitates early prion pathogenesis. Nat. Med. 7: 488-492.
14. MANDERSON, A.P. et al. 2001. Continual low-level activation of the classical complement pathway. J. Exp. Med. 194: 747-756.
15. BAL-PRICE, A. & G.C. BROWN. 2001. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21: 6480-6491.
16. THEOHARIDES, T.C. 1990. Mast cells: the immune gate to the brain. Life Sci. 46: 607-617.
17. WOOLHISER, M.R. et al. 2004. Activation of human mast cells by aggregated IgG through FcRI: additive effects of C3a. Clin. Immunol. 110: 172-180.
18. SAYAH, S. et al. 2003. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res. Mol. Brain Res. 112: 53-60.
19. JAUNEAU, A.C. et al. 2003. Complement component anaphylatoxins upregulate chemokine expression by human astrocytes. FEBS Lett. 537: 17-22.
20. TAKANO, T. et al. 2001. Complement C5b-9 induces cyclooxygenase-2 gene transcription in glomerular epithelial cells. Am. J. Physiol. Renal Physiol. 281: F841-F850.
21. TAKANO, T. & A.V. CYBULSKY. 2000. Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells: role of cyclooxygenase-1 and -2. Am. J. Pathol. 156: 2091-2101.
22. SPIELMAN, L. et al. 2002. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 103: 157-162.
23. SHEN, Y. et al. 1997. Characterization of neuronal cell death induced by complement activation. Brain Res. Protocols 1: 186-194.
24. MEAD, R.J. et al. 2002. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 168: 458-465.
25. ESPELAND, M.A. et al. 2004. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291: 2959-2968.
26. HENDERSON, V.W. et al. 2005. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76: 103-105.
27. AISEN, P.S. et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 54: 588-593.
28. KANATANI, K. et al. 2004. Effects of indomethacin and rofecoxib on gastric mucosal damage in normal and Helicobacter pylori-infected mongolian gerbils. J. Physiol. Pharmacol. 55: 207-222.
29. MAMDANI, M. et al. 2004. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363: 1751-1756.
30. GARCIA RODRIGUEZ, L.A. et al. 2004. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000-3006.
31. WOLFE, F., S. ZHAO & D. PETTITT. 2004. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J. Rheumatol. 31: 1143-1151.
32. VERRICO, M.M. et al. 2003. Adverse drug events involving COX-2 inhibitors. Ann. Pharmacother. 37: 1203-1213.
33. KIYOSHI, N. et al. 2000. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 20: 763-770.
34. TEATHER, L.A., M.G. PACKARD & N.G. BAZAN. 2002. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn. Mem. 9: 41-47.
35. MINGHETTI, L. 2004. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63: 901-910.
36. CHEN, C. & N.G. BAZAN. 2005. Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J. Neurophysiol. 93: 929-941.
37. LEE, E.O., Y.J. SHIN & Y.H. CHONG. 2004. Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor. J. Neuroimmunol. 155: 21-31.
38. AISEN, P. S. et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289: 2819-2826.
39. REINES, S. A. et al. 2004. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66-71.
40. SCHARF, S. et al. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53: 197-201.
41. ROGERS, J. et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611.
42. AISEN, P.S., J. SCHMEIDLER & G.M. PASINETTI. 2002. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58: 1050-1054.
43. KULKARNI, A.P. et al. 2004. Neuroprotection from complement-mediated inflammatory damage. Ann. N.Y. Acad. Sci. 1035: 147-164.
44. REYNOLDS, D.N. et al. 2003. Vaccinia virus complement control protein modulates inflammation following spinal cord injury. Ann. N.Y. Acad. Sci. 1010: 534-539.
45. REYNOLDS, D.N. et al. 2004. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann. N.Y. Acad. Sci. 1035: 165-178.
46. HICKS, R.H. et al. 2002. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19: 705-714.
47. KOTWAL, G.J., D.K. LAHIRI & R. HICKS. 2002. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann. N.Y. Acad. Sci. 973: 317-322.
48. DAVOUST, N. et al. 1999. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163: 6551-6556.
49. WHISS, P.A. 2002. Pexelizumab Alexion (abstr). Curr. Opin. Invest. Drugs 3: 870-877.
50. KAPLAN, M. 2002. Eculizumab (Alexion) (abstr). Curr. Opin. Invest. Drugs 3: 1017-1023.
51. SHERNAN, S.K. et al. 2004. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann. Thorac. Surg. 77: 942-949.
52. VERRIER, E.D. et al. 2004. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial (cardiovascular surgery abstr). JAMA 291: 2319-2327.
53. MIN, B.S. et al. 2003. Anti-complement activity of constituents from the stem-bark of Juglans mandshurica. Biol. Pharm. Bull. 26: 1042-1044.
54. KAWAKAMI, F., Y. SHIMOYAMA & K. OHTSUKI. 2003. Characterization of complement C3 as a glycyrrhizin (GL)-binding protein and the phosphorylation of C3alpha by CK-2, which is potently inhibited by GL and glycyrrhetinic acid in vitro. J. Biochem. 133: 231-237.
55. KROES, B.H. et al. 1999. Inhibition of human complement by beta-glycyrrhetinic acid. Immunology 90: 115-120.
56. GEETHA, T. & P. VARALAKSHMI. 1999. Anticomplement activity of triterpenes from Crataeva nurvala stem bark in adjuvant arthritis in rats. Gen. Pharmacol. 32: 495-497.
57. PIERONI, A. et al. 2000. Studies on anti-complementary activity of extracts and isolated flavones from Ligustrum vulgare and Phillyrea latifolia leaves (Oleaceae). J. Ethnopharmacol. 70: 213-217.
58. CIMANGA, K. et al. 2003. Complement-Inhibiting Iridoids from Morinda morindoides. J. Nat. Prod. 66: 97-102.
59. CIMANGA, K. et al. 1995. In vitro anticomplementary activity of constituents from Morinda morindoides. J. Nat. Prod. 58: 372-378.
60. NICHOLL, D.S. et al. 2001. In vitro studies on the immunomodulatory effects of extracts of Osbeckia aspera. J. Ethnopharmacol. 78: 39-44.
61. NORES, M.M. et al. 1997. Immunomodulatory activities of Cedrela lilloi and Trichilia elegans aqueous leaf extracts. J. Ethnopharmacol. 55: 99-106.
62. VAN DER NAT, J.M. et al. 1989. Characterization of anti-complement compounds from Azadirachta indica (abstr). J. Ethnopharmacol. 27: 15-24.
63. KAPIL, A. & S. SHARMA. 1997. Immunopotentiating compounds from Tinospora cordifolia. J. Ethnopharmacol. 58: 89-95.
64. IVANOVSKA, N. et al. 1999. Complement modulatory activity of bisbenzylisoquinoline alkaloids isolated from Isopyrum thalictroides. I. Influence on classical pathway in human serum. Int. J. Immunopharmacol. 21: 325-336.
65. IVANOVSKA, N., M. HRISTOVA & S. PHILIPOV. 1999. Complement modulatory activity of bisbenzylisoquinoline alkaloids isolated from Isopyrum thalictroides. II. Influence on C3-9 reactions in vitro and anti-inflammatory effect in vivo. Int. J. Immunopharmacol. 21: 337-347.
66. APERS, S. et al. 2002. Characterisation of new oligoglycosidic compounds in two Chinese medicinal herbs. Phytochem. Anal. 13: 202-206.
67. PARK, S.H. et al. 1999. Acylated flavonol glycosides with anti-complement activity from Persicaria lapathifolia. Chem. Pharm. Bull. 47: 1484-1486.
68. SAHU, A., N. RAWAL & M.K. PANGBURN. 1999. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem. Pharmacol. 57: 1439-1446.
69. AL-SEREITI, M.R. et al. 1999. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Ind. J. Exp. Biol. 37: 124-130.
70. PEAKE, P.W. et al. 1991. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase (abstr). Int. J. Immunopharmacol. 13: 853-857.
71. THOMET, O.A. et al. 2001. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. Biochem. Pharmacol. 61: 1041-1047.
72. STRUNK, R.C. et al. 1979. Inhibition of in vitro synthesis of the second (C2) and fourth (C4) components of complement in guinea pig peritoneal macrophages by a soybean oil emulsion. Pediatr. Res. 13: 188-193.
73. KOSASI, S. et al. 1989. Inhibitory activity of Jatropha multifida latex on classical complement pathway activity in human serum mediated by a calcium-binding proanthocyanidin (abstr). J. Ethnopharmacol. 27: 81-89.
74. T'HART, L.A. et al. 1989. An anti-complementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera (abstr). Planta Med. 55: 509-512.
75. HART, L.A. et al. 1988. Two functionally and chemically distinct immunomodulatory compounds in the gel of Aloe vera [abstr]. J. Ethnopharmacol. 23: 61-71.
76. KROES, B.H. et al. 1993. Fermentation in traditional medicine: the impact of Woodfordia fruticosa flowers on the immunomodulatory activity, and the alcohol and sugar contents of Nimba arishta [abstr]. J. Ethnopharmacol. 40: 117-125.
77. VAN DEN BERG, A.J. et al. 1995. Curcacycline A: a novel cyclic octapeptide isolated from the latex of Jatropha curcas L. FEBS Lett. 358: 215-218.
78. SHAHAT, A.A. et al. 2003. Anticomplement and antioxidant activities of new acetylated flavonoid glycosides from Centaurium spicatum (abstr). Planta Med. 69: 1153-1156.
79. CHIOU, W.F. et al. 2003. Anti-inflammatory properties of piperlactam S: modulation of complement 5a-induced chemotaxis and inflammatory cytokines production in macrophages. Planta Med. 69: 9-14.
80. ZHAO, J.F. et al. 1993. Anti-complementary acidic polysaccharides from roots of Lithospermum euchromum (abstr). Phytochemistry 34: 719-724.
81. PIERONI, A. et al. 1996. In vitro anti-complementary activity of flavonoids from olive (Olea europaea L.) leaves. Pharmazie 51: 765-768.
82. SHAHAT, A.A. et al. 1996. Anti-complementary activity of Crataegus sinaica (abstr). Planta Med. 62: 10-13.
83. THABREW, M.I. et al. 1991. Immunomodulatory activity of three Sri-Lankan medicinal plants used in hepatic disorders. J. Ethnopharmacol. 33: 63-66.
84. YAMADA, H. et al. 1985. Studies on polysaccharides from Angelica acutiloba. IV. Characterization of an anti-complementary arabinogalactan from the roots of Angelica acutiloba Kitagawa (abstr). Mol. Immunol. 22: 295-304.
85. BLONDIN, C. et al. 1996. Relationships between chemical characteristics and anticomplementary activity of fucans. Biomaterials 17: 597-603.
86. BENENCIA, F., M.C. COURREGES & F.C. COULOMBIE. 2000. Anti-inflammatory activities of Trichilia glabra aqueous leaf extract. J. Ethnopharmacol. 71: 293-300.
87. IVANOVSKA, N.D. et al. 1995. Immunomodulatory action of propolis. V. Anticomplementary activity of a water-soluble derivative. J. Ethnopharmacol. 47: 135-143.